The U.S. Food and Drug Administration (FDA) has expanded the approval of Foundation Medicine’s FoundationOne Liquid CDx as a companion diagnostic test for identifying advanced or metastatic breast cancer patients suitable for treatment with Novartis‘ Piqray (alpelisib). The approval covers men and postmenopausal women who have experienced disease progression during or after endocrine therapy. Additional new indications include those for patients with advanced ovarian cancer who may benefit from treatment with Rubraca (rucaparib) and for treatment with Alecensa (alectinib) in patients with…
You must be logged in to read/download the full post.
The post FDA Approves FoundationOne Liquid CDx as Companion Diagnostic Test for Piqray Treatment appeared first on BioNewsFeeds.